Literature DB >> 26451308

Therapeutic potential of interleukin-27 against cancers in preclinical mouse models.

Izuru Mizoguchi1, Yukino Chiba1, Jun-Ichi Furusawa1, Mingli Xu1, Ren Tsunoda1, Kaname Higuchi1, Takayuki Yoshimoto1.   

Abstract

Since we first reported the antitumor efficacy of IL-27 in 2004, accumulating evidence obtained by several groups using a variety of preclinical mouse models indicates that IL-27 possesses potent antitumor activity against various types of tumors through multiple mechanisms depending on the characteristics of individual tumors without apparent adverse effects.

Entities:  

Keywords:  IL-27; TLR3; TRAIL; antitumor; poly(I:C)

Year:  2015        PMID： 26451308      PMCID： PMC4589049          DOI： 10.1080/2162402X.2015.1042200

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Antiangiogenic and antitumor activities of IL-27.

Authors:  Motomu Shimizu; Mariko Shimamura; Toshiyuki Owaki; Masayuki Asakawa; Koji Fujita; Motoshige Kudo; Yoichiro Iwakura; Yasutaka Takeda; Andrew D Luster; Junichiro Mizuguchi; Takayuki Yoshimoto
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

2.  A requirement of dendritic cell-derived interleukin-27 for the tumor infiltration of regulatory T cells.

Authors:  Siyuan Xia; Jun Wei; Jingya Wang; Huayan Sun; Wenting Zheng; Yangguang Li; Yanbo Sun; Huiyuan Zhao; Song Zhang; Ti Wen; Xinglong Zhou; Jian-Xin Gao; Puyue Wang; Zhenzhou Wu; Liqing Zhao; Zhinan Yin
Journal:  J Leukoc Biol       Date:  2014-01-17       Impact factor: 4.962

3.  Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.

Authors:  Shuntaro Oniki; Hiroshi Nagai; Tatsuya Horikawa; Junya Furukawa; Maria Laura Belladonna; Takayuki Yoshimoto; Isao Hara; Chikako Nishigori
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

4.  Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma.

Authors:  Claudia Cocco; Nicola Giuliani; Emma Di Carlo; Emanuela Ognio; Paola Storti; Manuela Abeltino; Carlo Sorrentino; Maurilio Ponzoni; Domenico Ribatti; Irma Airoldi
Journal:  Clin Cancer Res       Date:  2010-06-29       Impact factor: 12.531

5.  IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells.

Authors:  Zhenzhen Liu; Jin-Qing Liu; Fatemeh Talebian; Lai-Chu Wu; Shulin Li; Xue-Feng Bai
Journal:  Eur J Immunol       Date:  2013-01-15       Impact factor: 5.532

6.  Potent antitumor activity of interleukin-27.

Authors:  Masayuki Hisada; Sadahiro Kamiya; Koji Fujita; Maria Laura Belladonna; Tatuya Aoki; Yasuhisa Koyanagi; Junichiro Mizuguchi; Takayuki Yoshimoto
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

7.  IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner.

Authors:  Yukino Chiba; Izuru Mizoguchi; Kana Mitobe; Kaname Higuchi; Hiroshi Nagai; Chikako Nishigori; Junichiro Mizuguchi; Takayuki Yoshimoto
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

8.  Interleukin-27 re-educates intratumoral myeloid cells and down-regulates stemness genes in non-small cell lung cancer.

Authors:  Irma Airoldi; Maria Grazia Tupone; Silvia Esposito; Marco V Russo; Giulia Barbarito; Giuseppe Cipollone; Emma Di Carlo
Journal:  Oncotarget       Date:  2015-02-28

9.  Interleukin-27 signaling promotes immunity against endogenously arising murine tumors.

Authors:  Karlo D T Natividad; Simon R Junankar; Norhanani Mohd Redzwan; Radhika Nair; Rushika C Wirasinha; Cecile King; Robert Brink; Alexander Swarbrick; Marcel Batten
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240
  9 in total
  3 in total

Review 1.  Regulation of myelopoiesis by proinflammatory cytokines in infectious diseases.

Authors:  Yukino Chiba; Izuru Mizoguchi; Hideaki Hasegawa; Mio Ohashi; Naoko Orii; Taro Nagai; Miyaka Sugahara; Yasunori Miyamoto; Mingli Xu; Toshiyuki Owaki; Takayuki Yoshimoto
Journal:  Cell Mol Life Sci       Date:  2017-12-07       Impact factor: 9.261

2.  Protective effects against tumors and infection by interleukin-27 through promotion of expansion and differentiation of hematopoietic stem cells into myeloid progenitors.

Authors:  Naoko Orii; Izuru Mizoguchi; Yukino Chiba; Hideaki Hasegawa; Mio Ohashi; Mingli Xu; Taro Nagai; Nakaba Ochiai; Yuki Mochizuki; Toshiyuki Owaki; Takayuki Yoshimoto
Journal:  Oncoimmunology       Date:  2018-01-15       Impact factor: 8.110

Review 3.  Expanding Diversity in Molecular Structures and Functions of the IL-6/IL-12 Heterodimeric Cytokine Family.

Authors:  Hideaki Hasegawa; Izuru Mizoguchi; Yukino Chiba; Mio Ohashi; Mingli Xu; Takayuki Yoshimoto
Journal:  Front Immunol       Date:  2016-11-04       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.